DK169329B1 - 1,3,4-trisubstitueret azetidin-2-on, farmaceutisk præparat indeholdende en sådan forbindelse og fremgangsmåde til fremstilling deraf - Google Patents

1,3,4-trisubstitueret azetidin-2-on, farmaceutisk præparat indeholdende en sådan forbindelse og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK169329B1
DK169329B1 DK170589A DK170589A DK169329B1 DK 169329 B1 DK169329 B1 DK 169329B1 DK 170589 A DK170589 A DK 170589A DK 170589 A DK170589 A DK 170589A DK 169329 B1 DK169329 B1 DK 169329B1
Authority
DK
Denmark
Prior art keywords
alkyl
compound
ethyl
azetidin
methyl
Prior art date
Application number
DK170589A
Other languages
Danish (da)
English (en)
Other versions
DK170589A (da
DK170589D0 (da
Inventor
Shrenik K Shah
Paul E Finke
James B Doherty
William Hagmann
Peter L Barker
Conrad P Dorn
Raymond A Firestone
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DK170589D0 publication Critical patent/DK170589D0/da
Publication of DK170589A publication Critical patent/DK170589A/da
Application granted granted Critical
Publication of DK169329B1 publication Critical patent/DK169329B1/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Reinforced Plastic Materials (AREA)
DK170589A 1988-04-11 1989-04-10 1,3,4-trisubstitueret azetidin-2-on, farmaceutisk præparat indeholdende en sådan forbindelse og fremgangsmåde til fremstilling deraf DK169329B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17968888A 1988-04-11 1988-04-11
US17968888 1988-04-11

Publications (3)

Publication Number Publication Date
DK170589D0 DK170589D0 (da) 1989-04-10
DK170589A DK170589A (da) 1989-10-12
DK169329B1 true DK169329B1 (da) 1994-10-10

Family

ID=22657566

Family Applications (1)

Application Number Title Priority Date Filing Date
DK170589A DK169329B1 (da) 1988-04-11 1989-04-10 1,3,4-trisubstitueret azetidin-2-on, farmaceutisk præparat indeholdende en sådan forbindelse og fremgangsmåde til fremstilling deraf

Country Status (21)

Country Link
EP (1) EP0337549B1 (fi)
JP (1) JP2736113B2 (fi)
KR (1) KR930008223B1 (fi)
CN (1) CN1037144A (fi)
AT (1) ATE128704T1 (fi)
AU (1) AU621865B2 (fi)
CA (1) CA1337990C (fi)
DE (1) DE68924439T2 (fi)
DK (1) DK169329B1 (fi)
ES (1) ES2079373T3 (fi)
FI (1) FI891689A (fi)
GR (1) GR3017656T3 (fi)
HU (1) HUT50761A (fi)
IE (1) IE891140L (fi)
IL (1) IL89835A0 (fi)
LV (1) LV11459B (fi)
NO (1) NO891470L (fi)
NZ (1) NZ228600A (fi)
PT (1) PT90222B (fi)
YU (1) YU71489A (fi)
ZA (1) ZA892549B (fi)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1992018488A1 (fr) * 1991-04-10 1992-10-29 Japan Tobacco Inc. Nouveau derive d'oxazinone
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
GB9103654D0 (en) * 1991-02-21 1991-04-10 Merck Sharp & Dohme Chemical process
US5104862A (en) * 1991-03-20 1992-04-14 Merck & Co., Inc. Bethalactam elastase inhibitors containing phosphorous acid derivatives at the 4-position of the 2-azetidinone
US5100880A (en) * 1991-03-20 1992-03-31 Merck & Co., Inc. Novel betalactam elastase inhibitors containing phosphorous acid derivatives at the 4-position of the 2-azetidinone
US5348953A (en) * 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
MY131273A (en) * 1991-07-23 2007-07-31 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
EP0529719A1 (en) * 1991-08-26 1993-03-03 Merck & Co. Inc. Assay for evaluating inhibition of PMN elastase by N-Substituted Azetidinones
US5274080A (en) * 1991-08-26 1993-12-28 Merck & Co., Inc. Monospecific antibodies useful in evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
US5276139A (en) * 1991-08-26 1994-01-04 Merck & Co., Inc. Haptens useful in evaluating inhibition of PNN elastase by N-substituted azetidinones
US5229267A (en) * 1991-08-26 1993-07-20 Merck & Co., Inc. Assay for evaluating inhibition of PMN elastase by N-substituted azetidinones
US5149838A (en) * 1991-09-20 1992-09-22 Merck & Co., Inc. Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
GB2266527A (en) * 1992-03-17 1993-11-03 Merck & Co Inc Substituted azetidinones useful in the treatment of leukemia
US5250676A (en) * 1992-03-23 1993-10-05 University Of Notre Dame Du Lac Process for the preparation of 3-substituted-2-azetidinones
CA2147129A1 (en) * 1992-10-27 1994-05-11 James B. Doherty New substituted azetidinones as anti-inflammatory and antidegenerative agents
MY128261A (en) * 1992-10-27 2007-01-31 Merck Sharp & Dohme New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5591737A (en) * 1992-12-17 1997-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1994013636A1 (en) * 1992-12-17 1994-06-23 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
GB9314350D0 (en) * 1993-07-12 1993-08-25 Zeneca Ltd Armide derivatives
US5420010A (en) * 1993-07-30 1995-05-30 Merck & Co., Inc. Assay for evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
CA2184385A1 (en) * 1994-03-11 1995-09-14 Philip Davies Composition for the treatment of lung disease
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
WO1996029307A1 (fr) * 1995-03-23 1996-09-26 Japan Tobacco Inc. Composes de diphenylmethyle-azetidinone et inhibiteur d'elastase
US5747485A (en) * 1995-04-13 1998-05-05 Merck & Co., Inc. Substituted azetidiones as anti-inflammatory and antidegenerative agents
US5523233A (en) * 1995-05-03 1996-06-04 Merck & Co., Inc. Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters
CZ422197A3 (cs) * 1995-07-01 1998-06-17 Smithkline Beecham Plc Azetidinonové deriváty, způsob jejich přípravy, meziprodukty tohoto postupu, farmaceutický prostředek obsahující tyto sloučeniny a použití těchto sloučenin jako léčiv
WO1997013750A1 (en) * 1995-10-09 1997-04-17 Chiroscience Limited Azetidinones and their therapeutic use as cytokine inhibitors
EP0869943A1 (en) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
CZ341098A3 (cs) * 1996-04-26 1999-03-17 Smithkline Beecham Plc Azetidinonové deriváty pro ošetřování aterosklerózy
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6242439B1 (en) * 1997-10-07 2001-06-05 Boehringer Ingelheim (Canada) Ltd. Azetidinone derivatives for the treatment of HCMV infections
DE69810800T2 (de) * 1997-10-07 2003-09-18 Boehringer Ingelheim (Canada) Ltd., Laval Azetidinonderivate zur behandlung von hcmv entzündungen
AU9425998A (en) * 1997-10-07 1999-04-27 Boehringer Ingelheim (Canada) Ltd. Azetidinone derivatives for the treatment of hcmv infections
WO1999064395A1 (en) * 1998-06-11 1999-12-16 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
EP1099690A4 (en) * 1998-07-23 2001-10-17 Shionogi & Co MONOCYCLIC BETA LACTAM COMPOUNDS AND CHYMASE INHIBITORS THAT CONTAIN THEM
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
CA2442219C (en) 2001-03-28 2007-09-11 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US8440819B2 (en) 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents

Also Published As

Publication number Publication date
IL89835A0 (en) 1989-12-15
LV11459A (lv) 1996-08-20
NO891470L (no) 1989-10-12
EP0337549A1 (en) 1989-10-18
ATE128704T1 (de) 1995-10-15
CN1037144A (zh) 1989-11-15
DK170589A (da) 1989-10-12
FI891689A (fi) 1989-10-12
IE891140L (en) 1989-10-11
JPH026471A (ja) 1990-01-10
FI891689A0 (fi) 1989-04-10
AU621865B2 (en) 1992-03-26
ZA892549B (en) 1989-11-29
KR900016121A (ko) 1990-11-12
DE68924439D1 (de) 1995-11-09
GR3017656T3 (en) 1996-01-31
NO891470D0 (no) 1989-04-10
DE68924439T2 (de) 1996-05-09
EP0337549B1 (en) 1995-10-04
ES2079373T3 (es) 1996-01-16
NZ228600A (en) 1992-02-25
PT90222B (pt) 1994-07-29
PT90222A (pt) 1989-11-10
HUT50761A (en) 1990-03-28
DK170589D0 (da) 1989-04-10
JP2736113B2 (ja) 1998-04-02
CA1337990C (en) 1996-01-23
YU71489A (en) 1991-10-31
LV11459B (en) 1996-12-20
AU3263089A (en) 1989-10-12
KR930008223B1 (ko) 1993-08-27

Similar Documents

Publication Publication Date Title
DK169329B1 (da) 1,3,4-trisubstitueret azetidin-2-on, farmaceutisk præparat indeholdende en sådan forbindelse og fremgangsmåde til fremstilling deraf
JP4199309B2 (ja) 新規アセトアミド誘導体およびプロテアーゼ阻害
US4680391A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
AU718918B2 (en) 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
NO160577B (no) Analogifremgangsmaate for fremstilling av antimikrobielt aktive eller b-laktamaseinhiberende 1-sulfo-2-oksoazetidinderivater.
US4866196A (en) Phenoxyacetic acid derivatives and preparation thereof
JPH0471073B2 (fi)
US6300337B1 (en) Acetamide derivative and use thereof
US5348953A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0207447A2 (en) Tetrazolyl derivatives of beta-lactams useful as elastase inhibitors
US4483861A (en) Antihypertensive sulfur-containing compounds
US5952321A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5808056A (en) Process for preparing substituted azetidinones
US4845088A (en) Tetrazolyl derivatives of beta-lactams useful as elastase inhibitors
DE69032857T2 (de) 2-spirocyclopropylcephalosporinderivate und verfahren zu ihrer herstellung
JPWO2003066671A1 (ja) エラスターゼ阻害作用を有する複素環式化合物およびその中間体
AU686780B2 (en) Composition for the treatment of lung disease
JP2005060379A (ja) 複素環式化合物からなる医薬
AU701386B2 (en) Process for preparing substituted azetidinones
FR2573761A1 (fr) Acylamino hydroxyalcanoyl amino et imino acides et esters a action therapeutique
KR20020028232A (ko) 피리미딘 유도체 화합물, 그 제조 방법 및 그 화합물을유효성분으로 하는 의약
FR2511372A1 (fr) Nouveaux derives de la cephalosporine et leur preparation
JPH02288876A (ja) 新規な世代の1,4―ジヒドロピリジン誘導体
JPH0321542B2 (fi)
WO2009045419A1 (en) Novel azetidinones useful as inhibitors of elastase

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
B1 Patent granted (law 1993)
PBP Patent lapsed

Country of ref document: DK